 | • レポートコード：B-MOR-08424 • 出版社/出版日：Mordor Intelligence / 2018年5月23日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・製薬 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、オーソバイオロジクスの世界市場について調べ、オーソバイオロジクスの世界規模、市場動向、市場環境、製品別（関節内補充療法製品、脱灰骨基質、合成オーソバイオロジクス、骨形成タンパク質、同種移植片、プラズマリッチプロテイン、骨髄穿刺濃縮細胞）分析、用途別（変形性関節症・変性関節炎、脊椎固定術 、軟組織の損傷、骨折回復、顎顔面・歯科アプリケーション）分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・オーソバイオロジクスの世界市場インサイト ・オーソバイオロジクスの世界市場環境 ・オーソバイオロジクスの世界市場動向 ・オーソバイオロジクスの世界市場規模 ・オーソバイオロジクスの世界市場規模：製品別（関節内補充療法製品、脱灰骨基質、合成オーソバイオロジクス、骨形成タンパク質、同種移植片、プラズマリッチプロテイン、骨髄穿刺濃縮細胞） ・オーソバイオロジクスの世界市場規模：用途別（変形性関節症・変性関節炎、脊椎固定術 、軟組織の損傷、骨折回復、顎顔面・歯科アプリケーション） ・オーソバイオロジクスの世界市場規模：エンドユーザー別 ・オーソバイオロジクスの世界市場：地域別市場規模・分析 ・オーソバイオロジクスの北米市場規模・予測 ・オーソバイオロジクスのアメリカ市場規模・予測 ・オーソバイオロジクスのヨーロッパ市場規模・予測 ・オーソバイオロジクスのアジア市場規模・予測 ・オーソバイオロジクスのインド市場規模・予測 ・オーソバイオロジクスの韓国市場規模・予測 ・関連企業情報・競争状況 |
The global orthobiologics market is projected to register a CAGR of about 5.4% during the forecast period, 2018-2023. Orthobiologics are used by orthopedic surgeons to help injuries heal more quickly. They are used to quicken the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally found in our body.
Increasing Patient Preference for Minimally Invasive Procedures
Orthobiologic therapy is a minimally invasive therapy and one of the components of regenerative medicine that are used to treat several musculoskeletal ailments, including degenerative osteoarthritis. Lately, orthobiologics have come to be known as one of the prominent treatment option for early osteoarthritis (OA) of the knee. The interests about orthobiologcs in the medical community and growing research in the field of regenerative medicine, coupled with promising clinical results from the use of orthobiologics are helping to make the clinical applications of this treatment more diverse every day. Biological therapy or cellular arthroplasty is evolving rapidly in the management of OA. Repair of damaged cartilage and biological restitution can be possible by the judicious use of autologous biological products. This will help the orthobiologics market to flourish during the forecast period.
High Cost Associated with Orthobiologics-Based Treatments
Treatments involving orthobiologics are expensive and often not covered by the governments. This is owing to the fact that this form of treatment is relatively new and there have not been enough studies to prove their efficacy and effectiveness in treating the patients. Also, the possibility of alternative form of treatments mean that patients who are skeptical about this form of treatment can opt for other alternative treatments available. This will lead to the slowdown of the growth of this market.
North America to Maintain Lead in the Market
North America is expected to command the largest share of the market in 2017 due to the increasing incidence of spinal disorders, rising geriatric and obese population, growing preference for minimally invasive procedures, and growing physician and patient awareness about newly introduced treatment procedures and technologies. However, Asia Pacific is expected to register the highest growth rate during the forecast period. The presence of a large geriatric and target patient population, high incidence of osteoarthritis and obesity, increasing government spending on healthcare, and improving healthcare infrastructure are some of the major factors driving the growth of the Asia Pacific orthobiologics market.
Key Developments:
• February 2018 – A conference was comducted that focused on orthobiologics at the Orthobiologic Singularity event, orthopedic medicine from invasive to regenerative.
• Sep 2017 – Bioventus, a global leader in orthobiologic solutions, announced that the US FDA approval was granted for DUROLANE, a single-injection, hyaluronic acid.
Major Players: ALLERGAN PLC., APOTEX INC., ASTELLAS PHARMA INC., AUROBINDO PHARMA LIMITED, COGENTIX MEDICAL INC., ENDO INTERNATIONAL PLC, HISAMITSU PHARMACEUTICAL CO. INC., INTAS PHARMACEUTICALS LTD, JOHNSON & JOHNSON, MACLEODS PHARMACEUTICALS LTD, MEDTRONIC PLC, MYLAN NV, PFIZER INC., SANOFI, AND TEVA PHARMACEUTICAL INDUSTRIES LIMITED, amongst others.
Reasons to Purchase the Report
• Current and future orthobiologics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence of Sports Injuries and Road Accidents
6.1.2 Increasing Incidence of Osteoarthritis
6.1.3 Rising Geriatric and Obese Population
6.1.4 Increasing Patient Preference for Minimally Invasive Procedures
6.2 Market Restraint
6.2.1 High Costs Associated With Orthobiologics-based Treatments
6.2.2 Preference for Alternative Treatment Options
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Viscosupplementation Products
7.1.2 Demineralized Bone Matrices
7.1.3 Synthetic Orthobiologics
7.1.4 Bone Morphogenic Protein
7.1.5 Allografts
7.1.6 Plasma-rich Protein
7.1.7 Bone Marrow Aspirate Concentrate
7.2 By Application
7.2.1 Osteoarthritis and Degenerative Arthritis
7.2.2 Spinal Fusion
7.2.3 Soft-tissue Injuries
7.2.4 Fracture Recovery
7.2.5 Maxillofacial and Dental Applications
7.3 By End User
7.3.1 Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
7.3.2 Research and Academic Institutes
7.3.3 Dental Clinics and Facilities
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 India
7.4.3.2 Australia & New Zealand
7.4.3.3 South korea
7.4.3.4 Rest of Asia-Pacific
7.4.4 Rest of the World
7.4.4.1 Saudi Arabia
7.4.4.2 Brazil
7.4.4.3 Others
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Arthrex Inc.
9.2 Bioventus LLC
9.3 Depuy Synthes (A Subsidiary of Johnson & Johnson)
9.4 Globus Medical Inc.
9.5 Harvest Technologies Corporation (A Terumo Bct Company)
9.6 K2M Group Holdings Inc.
9.7 Kuros Biosciences Ltd
9.8 Medtronic PLC
9.9 Nuvasive Inc.
9.10 Orthofix International NV
9.11 RTI Surgical Inc.
9.12 Seaspine Holdings Corporation
9.13 Stryker Corporation
9.14 Xtant Medical Holdings Inc.
9.15 Zimmer Biomet Holdings Inc.
*List not Exhaustive
10. Future of the Market